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Abstract
Background: It is argued that, the efficacy of anti-malarials could be prolonged through policy-mediated reductions in 
drug pressure, but gathering evidence of the relationship between policy, treatment practice, drug pressure and the 
evolution of resistance in the field is challenging. Mathematical models indicate that drug coverage is the primary 
determinant of drug pressure and the driving force behind the evolution of drug resistance. These models show that 
where the basis of resistance is multigenic, the effects of selection can be moderated by high recombination rates, 
which disrupt the associations between co-selected resistance genes.
Methods: To test these predictions, dhfr and dhps frequency changes were measured during 2000-2001 while SP was 
the second-line treatment and contrasted these with changes during 2001-2002 when SP was used for first-line 
therapy. Annual cross sectional community surveys carried out before, during and after the policy switch in 2001 were 
used to collect samples. Genetic analysis of SP resistance genes was carried out on 4,950 Plasmodium falciparum 
infections and the selection pressure under the two policies compared.
Results: The influence of policy on the parasite reservoir was profound. The frequency of dhfr and dhps resistance 
alleles did not change significantly while SP was the recommended second-line treatment, but highly significant 
changes occurred during the subsequent year after the switch to first line SP. The frequency of the triple mutant dhfr 
(N51I,C59R,S108N) allele (conferring pyrimethamine resistance) increased by 37% - 63% and the frequency of the 
double A437G, K540E mutant dhps allele (conferring sulphadoxine resistance) increased 200%-300%. A strong 
association between these unlinked alleles also emerged, confirming that they are co-selected by SP.
Conclusion: The national policy change brought about a shift in treatment practice and the resulting increase in 
coverage had a substantial impact on drug pressure. The selection applied by first-line use is strong enough to 
overcome recombination pressure and create significant linkage disequilibrium between the unlinked genetic 
determinants of pyrimethamine and sulphadoxine resistance, showing that recombination is no barrier to the 
emergence of resistance to combination treatments when they are used as the first-line malaria therapy.
Background
In a new era of anti-malarial treatment it is important to
examine the use of past drugs and to determine which
drug use practices are most likely to preserve drug effi-
cacy and to examine their specific importance across a
range of malaria endemicity settings. High recombination
rates associated with high malaria transmission found in
much of sub-Saharan Africa [1] have the potential to
delay the emergence of resistance by disrupting associa-
tions between the multigenic components of resistance
[2-4]. This consideration is important when resistance is
multigenic, as is the case with chloroquine, quinine [5,6]
and SP [7], and will certainly be the case with the new
artemisinin-based combination therapy (ACT). Mathe-
matical models indicate that drug coverage is the primary
determinant of drug pressure and the driving force
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behind the evolution of drug resistance [3,4]. These mod-
els show that where the basis of resistance is multigenic,
the effects of selection can be moderated by high recom-
bination rates, which disrupt the associations between
co-selected resistance genes. In this study, the interplay
between drug coverage, and the frequency of resistance
genes in Plasmodium falciparum populations were exam-
ined in a highly endemic region of Africa [1]. Genetic
changes occurring in the parasite reservoir of two rural
sites in Tanzania were measured over a period of transi-
tion from low SP coverage while chloroquine was first-
line treatment of uncomplicated malaria to higher cover-
age after SP became the first-line treatment.
The genetic determinants of pyrimethamine resistance
are point mutations at codons 16, 50, 51, 59, 108 and 164
of the dhfr gene [8,9]. Genetic determinants of sulpha-
doxine resistance are mutations found at codons 436, 437,
540, 581 and 613 of the dhps gene [10,11]. In African P.
falciparum, the presence of three dhfr mutations (N51I,
C59R, S108N) together with two dhps mutations (A437G,
K540E) prior to treatment is a significant predictor of SP
treatment failure [12-14]. In southeast Africa,
pyrimethamine resistance became established prior to
sulphadoxine resistance. This was evidenced by in-vitro
studies in Kenya, which showed that pyrimethamine
resistance was common as early as 1988, while sulpha-
doxine resistance did not appear until 1993-1995 [15].
Molecular genetic studies have corroborated the in-vitro
observations, showing that double mutant dhfr was pres-
ent in Kisumu, Kenya at least as early as 1981 [16], while
resistant dhps only appeared between 1993 and 1995 [17].
The emergence of the dhps  double mutant (A437G
K540E) on a background of resistant dhfr coincided with
the emergence of clinically evident SP resistance in
Africa. The dhps  double mutant (A437G, K540E) was
first recorded in Kenya between 1993 and 1995 [17], Tan-
zania in 1995 [18], and it was first seen in Malawi in 1995/
1996 [19]. In north-eastern Sudan, it was absent in 1993
but had appeared by 1998 [20], and in KwaZulu Natal,
South Africa, it was absent in 1995/1996 but had
appeared by 1999 [21]. Analysis of microsatellite poly-
morphisms around resistant dhfr and dhps suggests that
underlying these events was a dispersal of the dhps dou-
ble mutant allele on a background of resistant dhfr
throughout eastern and southern Africa [21].
Treatment of malaria in Tanzania is typically guided by
official recommendations from the Ministry of Health
and Social Welfare regarding drugs of choice for various
situations. "First-line" treatment refers to the drug offi-
cially recommended as the drug of first choice for the
treatment of uncomplicated malaria. "Second-line" treat-
ment refers to the drug officially recommended as an
alternative primarily to be used for treatment of patients
in whom the first line treatment failed to clear the infec-
tion and other select patients. "Third-line" treatment typ-
ically refers to the drug recommended for severely ill
patients. In practice, few treatment failures are recog-
nized and patients are often moved directly from first to
third line treatment, consequently, little second line drug
is used compared to the first line drug. SP replaced chlo-
roquine as the recommended first line treatment on the
Tanzanian mainland in August 2001. Prior to that SP was
the recommended second line treatment. A survey of SP
efficacy prior to national policy change showed a marked
regional variability within Tanzania with clinical efficacy
ranging between 76% in Tanga and 93% in Mwanza [22].
Tanga, in north-east Tanzania, was the first site in Africa
where SP treatment failure was reported [23,24]. Our
investigation took place in Kilombero/Ulanga and Rufiji
Districts which are located > 400 km from Tanga and
where resistance has been slower to appear. A study
among children aged 6-59 months in Kilombero during
1999 found parasitological clearance was 94% over 28
days of follow-up after SP treatment [25].
To examine the genetic change at dhfr and dhps loci
under first and second line SP use in Kilombero/Ulanga
and Rufiji Districts, malaria parasite samples were col-
lected from residents of randomly selected households in
the two districts, in a series of cross sectional surveys,
over an area covering 29,400 km2 and including sites up
to 300 km apart. Three cross sectional surveys were per-
formed. The first survey occurred during July-September
2000, when CQ was first-line treatment and SP was sec-
ond line. The second survey in July -September 2001
coincided with the implementation of a new national pol-
icy recommending use of SP as the first-line treatment of
uncomplicated malaria. The third survey, in July-Septem-
ber 2002, occurred approximately one year after imple-
m e n t a t i o n  o f  t h a t  p o l i c y  c h a n g e .  I n  a l l ,  t h e  s u r v e y s
included 20,062 participants and yielded parasites from
4,950 malaria infections. By comparing genetic change
between 2000 and 2001 with that which occurred
between 2001 and 2002, the impact of the policy change
on the genetic composition of the parasite population
was quantified. Infections identified at community level
include both symptomatic and asymptomatic partici-
pants. This method of sampling is preferable to sampling
at a health clinic where by definition all infections are
symptomatic, and many might have been pretreated.
Since resistant parasites are selected by pre-treatment,
the active surveillance approach yields a less biased sam-
ple of the circulating parasite population at community
level.
Methods
Study area, subjects and samples
Community surveys were conducted during July, August
and September of 2000, 2001 and 2002 in three rural dis-Malisa et al. Malaria Journal 2010, 9:190
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tricts of south-eastern Tanzania, Rufiji (Population =
170,000), Kilombero (Population = 220,000) and Ulanga
(Population = 160,000). The three districts were well
matched in terms of predicted intensity and duration of
malaria transmission and risk (MARA), relative access
and overall utilization of health services (based on sur-
veys), fairly usage of insecticide treated nets (ITNs) and
relative proportion of urban peri-urban, rural population.
The surveys were part of large combination therapy pilot
implementation programme in Tanzania, the Interdisci-
plinary Monitoring Programme for Antimalarial Combi-
nation Therapy (IMPACT-TZ). IMPACT-Tanzania is a
multiyear implementation research evaluation that rests
on a collaborative platform incorporating the US Center
for Disease Control and Prevention (CDC), the Ifakara
Health Institute, London School of Hygiene and Tropical
Medicine, and the Ministry of Health and Social Welfare
including its National Malaria Control Programme, the
Tanzania Essential Health Interventions Project and the
Council Health Management Teams of Rufiji, Kilombero,
Ulanga, Morogoro and Mvomero Districts. IMPACT-
Tanzania is primarily supported by funding from the
United States Agency for International Development,
CDC and Wellcome Trust. For the purpose of the study,
Kilombero and Ulanga Districts were treated as a single
district because population movement between these two
districts is high and the study population spans the bor-
der region. Plasmodium falciparum malaria transmission
in the study area is intense (with an estimated entomolog-
ical inoculation rate of 367 infectious bites per person per
year [1]) and perennial with some seasonal fluctuation. A
total of 20,062 adults and children belonging to randomly
selected households participated in the study. A finger-
prick blood sample for blood slide and filter paper blood-
spot were collected from each individual in the house-
hold. The filter paper bloodspots were air-dried and
stored at room temperature in self-sealing plastic bags
with dessicant and stored dry at room temperature. All
blood slide samples were screened by light microscopy
for P. falciparum parasites. Bloodspots from microscopi-
cally positive subjects were selected and preserved at
room temperature for molecular genotyping.
Ethics
Scientific and ethical clearance was granted from the
Medical Research Council of the National Institute for
Medical Research in Tanzania, the Centers for Disease
Control and Prevention, USA, and the London School of
Hygiene and Tropical Medicine. Written informed con-
sent was obtained from all individuals or their guardians
before collection of samples.
DNA extraction
The DNA was extracted from bloodspots dried on filter
papers. A section of the dried blood spot filter paper was
excised using a sterile blade or scissors, and soaked in a 1
ml, 0.5% saponin-1× phosphate buffered saline (PBS)
overnight in a 96-deepwell plate. The section of filter
p a p e r  w a s  t h e n  w a s h e d  t w i c e  i n  1  m l  o f  1 ×  P B S  a n d
finally, was boiled for 8 min in 100 μl PCR quality water
with 50 μl 20% chelex suspension (pH 9.5).
PCR amplification
Nested PCR was used to amplify a 594 base pair (bp) frag-
ment of dhfr and a 711 bp fragment of dhps each contain-
ing the sequence where mutations are found. Primer
sequences and PCR reaction conditions were previously
described in [25]. PCR was performed in 96 well plates
with 25-μl PCR reaction volumes containing final con-
centrations of 0.25 μM oligonucleotide primers, 2 mM
MgCl2, 250 μM each deoxyribonucleotide triphosphate
(dNTPs), and 1× Taq polymerase. 1 μl of DNA template
was used in the outer (primary) PCR reaction mixture for
dhfr and dhps amplifications. For the inner (secondary)
dhps reactions 1 μl of the outer PCR product was used.
The outer dhfr  PCR products were diluted three fold
before 1 μl was introduced into the inner PCR reaction
mixtures.
Molecular genotyping of point mutations by sequence 
specific oligonucleotide probing (SSOP)
The amplified PCR products were screened for dhfr and
dhps sequence variants at 10 loci where single nucleotide
polymorphisms (SNPs) related to anti-malarial drug
resistance are known to occur. The sequence changes
(and the amino acid substitutions they code for) are sum-
marized in Table 1.
PCR products were spotted in a 12 by 8-grid and cross
linked onto nylon membranes and probed for sequence
polymorphisms by hybridization to specific oligonucle-
otide probes described previously [26]. For analysis of
samples collected in 2000, the visualization of hybridized
digoxygenin labelled probes on membranes was per-
formed by the alkaline phosphatase-catalysed breakdown
of the CSPD substrate (Roche Boehringer Mannheim,
Mannheim, Germany) and visualized by exposure on
Hyperfilm-ECL (Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, United Kingdom), accord-
ing to Boehringer Mannheim recommendations and pre-
viously described [27]. For analysis of samples collected
in 2001 and 2002 the probed blots were visualized using
ECF substrate and detection using a phosphoimager
(STORM®). Inspection of autoradiographic films was car-
ried out by light box illumination, while the phophoim-
ager output was recorded through viewing of digitally-
captured images of chemifluorescent signal. The change
in the method by which probe hybridization signal was
visualized did not affect the results in any way since the
probes and hybridization conditions were unchanged.Malisa et al. Malaria Journal 2010, 9:190
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The stringency and specificity of the hybridization pro-
cess was confirmed by inspection of a series of 4 controls
with a known single genotype variant sequence. All blots
with non-specifically bound probes were stripped and re-
probed. A SNP was considered to be present in the PCR
product when the intensity of signal was higher than that
of the background. The blots were scored independently
by two people.
In this analysis, the aim was to establish the relative
abundance of different point mutation haplotypes at dhfr
and dhps. Since bloodstage P. falciparum is haploid, this
is very straightforward when an infection consists of a
single genotype because only one form of sequence at
every SNP locus is seen. When infections are composed
of multiple genotypes a mixture of different sequence
variants occurs making the inference of point mutation
haplotypes within that infection more difficult.
The presence, absence, and relative abundance of
hybridization signal for every probe were recorded at
each locus. A sample was considered to have a single hap-
lotype when only one sequence variant was found at each
locus. Blood samples were categorized as having a single,
a majority, or a mixture of sequence at each SNP locus.
Majority and mixed genotype infections were differenti-
ated according to the relative intensity of signal. If the
hybridization signal of the minority sequence was greater
than half the intensity of the majority then an infection
was classified as mixed. To determine the relative abun-
dance of different point mutation haplotypes in the para-
site population, one haplotype only was counted from
each infection and those mixed infections where haplo-
types could not be resolved were omitted from the calcu-
lation of haplotype frequencies. Hence, frequency data is
based upon a subset of isolates which were either
unmixed or had a predominating majority haplotype. A
breakdown of the proportions of isolates which success-
fully PCR amplified and which were genotyped as single,
majority or mixed haplotype infections is given in Table
2.
Statistical analysis
Statistical comparison of allele frequencies at dhfr and
dhps  in the various sites was carried out using chi-
squared analysis in STATA version 9.2 [28]. The calcula-
Table 1: The nucleotide and amino acid substitutions at (a) dhfr and (b) dhps genes screened for by PCR-SSOP
dhfr
Codon 50 51 59 108 164
Wild type Cys (C) TGT Asn (N) AAT Cys (C) TGT Ser (S) AGC Ile (I) ATA
AAC
Mutant Arg (R) Ile (I) Arg (R) Asn (N) Leu (L)
CGT ATT CGT AAC TTA
Thr (T)
ACC
dhps
Codon 436 437 540 581 613
Wild type Ser (S) Ala (A) Lys (K) Ala (A) Ala (A)
TCT GCT AAA GCG GCC
Mutant Phe (F) Gly (G) Glu (E) Gly (G) Ser (S)
TTT GGT GAA GGG TCC
Ala (A) Thr (T)
GCT ACC
Cys (C)
TGTMalisa et al. Malaria Journal 2010, 9:190
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tion of binomial exact 95% confidence intervals was car-
ried out using STATA version 9.2. Linkage disequilibrium
analysis was performed using Arlequin software.
Role of the funding source
This study was funded through an interagency agreement
between the United States Agency for International
Development (USAID) and CDC and a cooperative
agreement between CDC and the Ifakara Health Institute
(IHI). USAID did not participate in the design, collection,
analysis, or interpretation of the data, in the writing of the
report, or in the decision to submit for publication.
Results
Of 20,062 people sampled, 4,950 were identified as
infected with P. falciparum. DNA was extracted from the
4,950 P. falciparum positive bloodspots and PCR amplifi-
cation of dhfr and dhps performed once, giving a com-
bined rate of PCR amplification success of 69% for both
genes (Table 2). The amplified products were screened
for all the variant sequences described in Table 1. Out of
the 3,436 isolates, which amplified successfully for dhfr,
71% were single or majority genotype infections and the
point mutation haplotypes could easily be resolved. Of
the 3,412 samples, which amplified successfully for dhps,
8 1 %  w e r e  s i n g l e  o r  m a j o r i t y  g e n o t y p e  w i t h  r e s o l v a b l e
haplotypes.
Allelic haplotypes at dhfr and dhps genes
The point mutations found in the dhfr gene were N51I,
C59R and S108N. They were found in the following hap-
lotypic arrangements NCS, NCN ,NRN, ICN and IRN
which are common throughout East Africa and have been
previously reported in Tanzania [26], Malawi [29], Kenya
[12,30], and Uganda [31,32]. Two rare combinations of
mutations were found; N51I with C59R (IRS) was found
in a single individual (previously reported in Uganda [31],
and C59R alone (NRS) was found in one sample only and
has not been previously reported, (again sequence confir-
mation of these rare haplotypes needs to be done).
Five dhps mutations were found (S436A, S436F, S436C,
A437G, and K540E) in nine distinct haplotypic arrange-
ments; five of which (SAK, AAK, SGE ,SGK, and SAE )
have been described previously in isolates from East
Africa [12,26,30-32] while the remaining four (CAK,
FAK, AAE ,and FAE) were found in extremely low fre-
quency and have not been reported before, presumably
because of their rarity, although sequencing confirmation
is also needed to verify their existence.
The change in frequency of the dhfr IRN and the dhps
SGE haplotypes, which have the greatest significance for
SP efficacy are shown in Figures 1a and 1b. Changes
occurring under the CQ policy (2000 to 2001) are mark-
edly different to those occurring under the SP policy
(2001-2002). The frequency of the dhps double mutant
Table 2: Annual survey 2000-2002, malaria positive samples and their PCR outcome in Rufiji and Kilombero/Ulanga 
populations.
Rufiji Kilombero Ulanga
Year 2000 2001 2002 2000 2001 2002
Survey population 2844 3285 3349 3289 3197 4098
P. falciparum positive 778 908 854 955 580 875
PCR amplified dhfr 549 683 687 404 488 686
PCR amplified dhps 521 592 725 444 347 720
Single or majority dhfr 455 420 527 376 238 489
83% 62% 77% 93% 49% 71%
Single or majority dhps 417 519 596 365 294 603
80% 88% 82% 82% 85% 84%
Single or majority dhfr+dhps 288 278 404 190 138 381
55% 47% 59% 47% 40% 55%Malisa et al. Malaria Journal 2010, 9:190
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A437G K540E, shown in Figure 1a, did not change signif-
icantly between 2000 and 2001 in either Rufiji (0.08-0.09)
(p > 0.411, 95% CI) or in Kilombero/Ulanga (0.13-0.11) (p
> 0.497, 95% CI). Contrastingly, there was a highly signifi-
cant change between 2001 and 2002 in both Rufiji (0.09-
0.25) (2.5 fold increase p ≤ 0.0001, 95% CI) and Kilo-
mbero/Ulanga (0.11-0.27) (2.6 fold increase p ≤ 0.0001).
The frequency of the dhps double mutant haplotype was
remarkably similar in Kilombero/Ulanga and Rufiji and
there were no significant differences between the two
sampling sites at any time point.
The change in frequency of the dhfr IRN and the dhps
SGE haplotypes, which have the greatest significance for
SP efficacy are shown in Figures 1a and 1b. Changes
occurring under the CQ policy (2000 to 2001) are mark-
edly different to those occurring under the SP policy
(2001-2002). The frequency of the dhps double mutant
A437G K540E, shown in Figure 1a, did not change signif-
icantly between 2000 and 2001 in either Rufiji (0.08-0.09)
(p > 0.411, 95% CI) or in Kilombero/Ulanga (0.13-0.11) (p
> 0.497, 95% CI). Contrastingly, there was a highly signifi-
cant change between 2001 and 2002 in both Rufiji (0.09-
0.25) (2.5 fold increase p ≤ 0.0001, 95% CI) and Kilo-
mbero/Ulanga (0.11-0.27) (2.6 fold increase p ≤ 0.0001).
The frequency of the dhps double mutant haplotype was
remarkably similar in Kilombero/Ulanga and Rufiji and
there were no significant differences between the two
sampling sites at any time point.
Changes in the frequency of the dhfr  triple mutant
allele IRN are shown in Figure 1b. The frequency was sig-
nificantly higher in Rufiji than in Kilombero/Ulanga at all
time points. Between 2000 and 2001, there was an
increase in frequency in both Kilombero/Ulanga (0.28-
0.31) (p > 0.400, 95% CI) and Rufiji (0.38-0.47) (p < 0.007,
95% CI), yet between 2001 and 2002 the increase was
greater and more highly significant in both Kilombero/
Ulanga (0.31-0.52) (p ≤ 0.0001, 95% CI) and Rufiji (0.47-
0.63) (p ≤ 0.0001, 95% CI).
In a further subset of samples where both dhfr and dhps
sequences were unmixed, it was possible to measure the
frequency of two locus genotypes. In figure 1c, the fre-
quency of the triple dhfr + double dhps genotype in the
two populations is compared. The initial frequency was
around 0.05 in both the districts and there was no change
between 2000 and 2001 in Kilombero/Ulanga (p > 0.824,
95% CI) or Rufiji (p > 0.186, 95% CI) but a remarkable 4
fold increase to frequencies of 0.21 and 0.24 occurred
between 2001 and 2002 in Kilombero/Ulanga (p < 0.0001,
95% CI) and Rufiji (p < 0.0001, 95% CI).
Haplotypes conferring intermediate levels of resistance
The effect of changing policy on the frequency of sensi-
tive and double mutant dhfr alleles is shown in Figure 2.
The increase of the triple mutant allele acted to displace
sensitive alleles, which show a substantial decline in Kilo-
mbero/Ulanga 2000-2001 (0.51-0.47) (p > 0.352, 95% CI),
2001-2002 (0.47-0.28) (p ≤ 0.0001, 95% CI) and Rufiji
2000-2001 (0.36-0.30) (p > 0.092, 95% CI) and 2001-2002
(0.30-0.18) (p ≤ 0.0001, 95% CI). The double mutant dhfr
alleles, which confer intermediate levels of resistance in-
vitro [33], neither increased nor decreased, remaining at a
frequency of around 10% in both sites throughout all sur-
veys.
As well as the highly resistant dhps A437G K540E dou-
ble mutant, a number of single 436 mutant alleles were
recorded. Among these, by far the most common was the
S436A, which was consistently found at frequencies of
10%-20% at all time points in both districts. Figure 3
Figure 1 Changes in the frequency of SP resistance genes in Kilo-
mbero/Ulanga (dotted line with diamonds) and Rufiji (solid line 
with squares) in cross sectional surveys in 2000, 2001, and 2002. 
Top graph is the frequency of the dhps double mutant allele, middle 
graph the frequency of dhfr triple mutant alleles and the bottom graph 
the frequency of triple mutant dhfr + double mutant dhps genotype.
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shows the frequencies of the sensitive S436A single
mutant and the A437G K540E double mutant alleles
through time in both districts. From these data it is clear
that the rising frequency of the double mutant allele dis-
placed the sensitive allele, which decreased significantly
during 2001-2002 in both Kilombero/Ulanga (0.7-0.6) (p
≤ 0.001, 95% CI) and Rufiji (0.77-0.60) (p ≤ 0.0001, 95%
CI). Interestingly, the frequency of the A436A allele
remained static at all time points in both sites.
Linkage disequilibrium
To examine the effect of simultaneous selection by
pyrimethamine on dhfr  and sulphadoxine on dhps, we
looked at two-locus genotypes sampled from both sites in
the three successive surveys. Taking the subset of samples
for which point mutation haplotypes could be unequivo-
cally resolved for both genes, we compared the observed
with expected frequencies generated from contingency
tables (given in full in Additional file 1). No significant
linkage disequilibrium was found between dhfr and dhps
loci in either 2000 or 2001. Since these surveys were both
conducted while SP was second-line therapy, the data was
pooled and, in Figure 4, linkage disequilibrium (d') is
compared under second line SP selection (2000 and 2001
combined) and during first line SP selection (in the 2002
survey). There was a significant association between the
dhfr  triple mutant allele and the dhps  double mutant
allele after the change in policy. In Kilombero/Ulanga
during 2000-2001, 17 of the 328 unmixed samples carried
the dhfr triple dhps double mutant genotype (d' = 0.1015,
p > 0.2885, 95% CI) while in Rufiji 2000-2001, 32 of 566
unmixed samples had the dhfr triple dhps double mutant
genotype (d' = 0.1821, p > 0.0760, 95% CI). By 2002 there
was a highly significant association between these alleles.
In Kilombero/Ulanga 84 of 381 unmixed samples carried
the dhfr triple dhps double mutant genotype and 64 were
'expected' (d' = 0.3633, p ≤ 0.0001, 95% CI) and in Rufiji
94 of 404 unmixed samples carried this same genotype
compared to 79 'expected' (d' = 0.3184, p ≤ 0.001, 95% CI).
The d' index of linkage disequilibrium, between the dhps
A437G + K540E double mutant and dhfr double mutant
allele was not significantly changed (Figure 4B) but a neg-
ative association between the dhps double mutant allele
and dhfr sensitives emerged under first line SP treatment
(Figure 4C) (Rufiji p ≤ 0.0001, 95% CI, and Kilombero/
Ulanga p ≤ 0.0001, 95% CI).
Figure 2 Allele frequency changes at dhfr in Rufiji (A), and Kilo-
mbero/Ulanga (B). The sensitive allele (dotted line with diamond), the 
triple mutant N51I + C59R + S108N allele (solid line with squares), and 
double mutant C59R + S108N (dash-dot line with triangles), double 
mutant N51I + S108N(dashed line with X).
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Figure 3 Allele frequency changes at dhps in Rufiji (A), and Kilo-
mbero/Ulanga (B). The sensitive allele (dotted line with diamonds), 
the double mutant A437G + K540E allele (solid line with triangles), and 
single S436A mutant (dashed line with squares).
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Measurement of haplotype frequencies
Measurement of haplotype frequencies is complicated by
the existence of mixed infections. If multiple haplotypes
are counted from mixed infections the frequency of rare
allelic haplotypes is overestimated. Haplotype frequency
measures presented were based solely on infections
where a single or majority haplotype was detected, and
only one haplotype was scored per individual infection,
while mixed infections were excluded because point
mutation haplotypes could not be determined. The over-
all proportion of mixed infections excluded from the fre-
quency estimations was 29% of infections for dhfr and
19% of infections for dhps.
To examine the extent of the underlying rate of mixture
in infections and test the robustness of this frequency
estimates, this study looked at three unlinked microsatel-
lite markers (Poly A, Pfpk2 and TA109) in 178 and 180
samples from 2002 survey from Kilombero/Ulanga and
Rufiji, respectively. The minimum number of co-infecting
genotypes in each infection was determined as the great-
est number of alleles at any of the three microsatellite
loci. This number is often referred to as the "multiplicity
of infection" or (MOI). In Figure 5 the distribution of
MOI in the two districts is compared showing that they
are similar. The presence/absence of dhps  A437G and
K540E among the same infections was used to test
whether the distribution of the dhps double mutant
alleles was consistent with expectation using a method
devised by Schneider et al [34] (see Additional file 1).
This uses maximum likelihood to predict the underlying
frequency of resistance alleles based on measures of the
multiplicity of infection and the presence/absence of
resistance mutations in those infections. The analysis
predicted an underlying frequency of the dhps  double
mutant of 0.276 in Rufiji (where the frequency among
single and majority genotype infections was 0.274) and a
frequency of 0.262 in Kilombero Ulanga (where the fre-
quency among single and majority genotype infections
was 0.245). The estimates using these two approaches are
very consistent showing that no obvious bias is intro-
duced into the estimation of frequencies by excluding
mixed infections.
The robustness of this approach for estimating allele
frequencies in populations sampled by blood survey has
been demonstrated in a study by Anderson et al [35]
comparing three different methods. All three methods
gave equivalent frequency values. The predominant allele
Figure 5 The minimum number of co-infecting genotypes (multi-
plicity of infection or MOI) was determined by measuring the 
number of alleles in every sample at 3 unlinked microsatellite loci 
(Poly A, Pfpk2 and TA109). Here the MOI in 178 samples from Kilo-
mbero/Ulanga 2002 (white) and 180 samples Rufiji 2002 (black) are 
compared.
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adopted in our study is favoured because it utilizes data
f r o m  a s  m a n y  i n d i vi d u a l s  as  po s s i b l e  w h i l e  s t i l l  g i vi n g
reliable haplotype data. Importantly the MoI did not vary
significantly between treatments at any time it therefore
cannot be the source of any systematic bias in our analy-
sis. Majority or minority, the genotypes important in the
spread of resistance must, by definition, appear in greater
frequency in subsequent surveys. The power of examin-
ing a series of cross sectional surveys is its capacity to
show the significant micro-evolutionary genetic changes
over time.
Discussion
Policy and genetic change
The influence of policy change on the genetic composi-
tion of the parasite population was profound. While the
frequency of dhfr and dhps alleles did not change signifi-
cantly during 12 months of first line CQ treatment and
second line SP, the switch to a policy of first line SP
caused the frequency of the triple mutant dhfr allele to
increase by 37% to 63% and the frequency of the double
mutant dhps allele to increase 200-300%. A combination
of these two alleles is predictive of SP treatment failure
in-vivo [12-14] and the rapid increase in the frequency of
this genotype from 5.5% to 22.7% between 2001 and 2002
is consistent with findings of a similar study in Mozam-
bique [36], yet suggests that the outlook for SP efficacy in
subsequent years would be increasingly bad. In fact, this
observation is borne out by the results of SP treatment
efficacy monitoring in south-east Tanzania during 2003
which found that 49% of SP treatments failed by day 28
[37]. A national policy decision was made in 2006 to
switch the recommended first-line treatment to arte-
mether plus lumefantrine combination treatment.
Household interviews conducted simultaneously
showed that there was a sharp increase in SP use after the
policy transition (a 5-6 fold increase between 2000 and
2002). Prior to the introduction of SP as first line therapy
SP was widely available for self-treatment via purchase
from shops [38], as well as through formal health facilities
as a second-line treatment. Although SP is currently
being replaced as the recommended first-line treatment
for malaria in Tanzania and much of the rest of Africa, it
will continue to be used in intermittent preventive treat-
ment of infants and pregnant women. The drug pressure
applied when SP use is restricted to intermittent pro-
grammes of treatment in infants and pregnant women
will more closely resemble the situation of 2000-2001.
The predicted consequences of more restricted use of SP
are, first, that the rate at which frequency of resistance
alleles increase should decline, and second, that the asso-
ciation between the triple mutant dhfr allele and double
mutant  dhps  allele maintained by high coverage drug
selection will diminish. Both these predictions pre-sup-
pose that the resistance alleles had not already become
fixed in the population.
The spread of resistance
For successful spread, a resistance mutant must be trans-
mitted at a faster rate than the sensitive form. This occurs
in the presence of drug pressure because of the differen-
tial survival and reproduction rates conferred by these
alleles. The population-wide rates of change observed in
the present study are attributable to changes in SP cover-
age during that period. In order to quantify drug pressure
under a specific policy intervention, its effect upon the
relative abundance, or frequency, of every haplotype
needs to be measured because each allele is subject to a
differing selection pressure by virtue of its differing resis-
tance properties.
The finding that first line use of SP brought about the
same genetic changes independently in Kilombero/
Ulanga and in Rufiji indicates they are likely to have
broad applicability elsewhere. But direct transposition to
predict rates in other settings should take into account
differences in access to drugs and in the infrastructure for
provision of healthcare services that can differ substan-
tially from country to country. Importantly, from a
molecular genetic perspective, recent studies in west and
central African countries still show the dhps  A437G,
K540E double mutant allele to be absent or very rare
[39,33,40]. Only once these alleles are established will the
rates of change observed here be predictive of change in
such populations.
Evolutionary history of resistance alleles
By following haplotype frequencies over time, the con-
trasting behaviors of mutant alleles which confer high,
intermediate or mild resistance were described. The fre-
quency of weakly resistant alleles such as the dhfr double
mutant and the dhps single mutant did not respond to the
increase in SP use. During the course of the three annual
surveys, both dhfr  double mutant alleles maintained a
steady frequency of around 10%, and the dhps  single
mutant maintained a frequency of around 15%. They
were neither displaced by the highly resistant alleles, as
the sensitive alleles were, nor did they increase in fre-
quency in response to elevated drug pressure.
Double mutant dhfr alleles are often regarded as pre-
cursors of the triple mutant since they can potentially
convert to the highly resistant triple mutant allele by the
simple acquisition of a single point mutation. Somewhat
surprisingly, flanking microsatellite analysis has shown
that the triple mutants in southeast Africa [21], and in the
Kilombero/Ulanga site specifically [41], belong to a single
lineage which originated in Asia [42]. The double mutant
dhfr alleles found in this site belong to a restricted num-
ber of independently derived lineages [21], which are inMalisa et al. Malaria Journal 2010, 9:190
http://www.malariajournal.com/content/9/1/190
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all probability of African origin. So while the increase in
frequency of triple mutant allele in Kilombero/Ulanga
and Rufiji can be explained by the expansion of the Asian
derived lineage under selection by SP treatment, the
steady persistence of the mildly resistant double mutant
dhfr lineages at around 10% requires some further expla-
nation. The existence of conserved flanking region
around them is evidence of selection [21] and there is fur-
ther evidence that double mutant dhfr alleles can gain fit-
ness advantage in specific circumstances. For example,
they have been associated with treatment failure in indi-
viduals who have not had sufficient exposure to malaria
to have acquired immunity [14,43] and while not affect-
ing clinical efficacy in Colombia, the N51I + S108N dou-
ble mutant was associated with prolonged parasite
clearance times and with gametocytaemia 14 and 28 days
after treatment, indicating they confer survival and
reproductive advantages [44]. It has also been proposed
that exposure to sub-therapeutic drug levels might select
for weakly resistant, or drug tolerant parasites which are
newly inoculated into people who recently received treat-
ment [45].
An alternative explanation for the continuing existence
of dhfr double mutant alleles is that they pre-date the use
of SP. Pyrimethamine was used as monotherapy during
the 1950s and 60s and numerous studies showed that
resistance quickly arose locally in response to drug pres-
sure [46-48]. Double mutant dhfr alleles could have been
the basis of these early reports of pyrimethamine resis-
tant malaria and may well have preceded the arrival of the
dhfr  triple mutant. Supporting evidence comes from
studies in Kenya where double mutant alleles were in the
majority in a panel of isolates collected as early as 19N51I
+ S108N; 21% and C59R + S108N; 47% (16). These
reports are concurrent with measures of intermediate
resistance of around 20% in Kilifi, coastal Kenya between
1984 and 1989. This rose to 92% between 1993 and 1995
[49], by which time the triple mutant was becoming more
prevalent in Kilifi [50].
The evolution of multi-drug resistance
By combining dhfr and dhps data the frequency of the
highly resistant dhfr-dhps genotype in each of three time
points was estimated. The frequency of this genotype
more than quadrupled between 2001 and 2002 in Kilo-
mbero/Ulanga and in Rufiji, and it also was found greatly
in excess of the numbers expected on the basis of random
association. Such population-wide associations between
unlinked resistance genes are expected to occur when
two drugs with independent modes of action are com-
bined, or where resistance to a single drug is controlled
by unlinked mutations. The association occurs because of
the combined effects of two selection processes which
occur simultaneously. The fully resistant parasites survive
better than genotypes with partial resistance. In addition,
the drug treatment itself promotes assortative mating
among resistant survivors of treatment by purging the co-
infecting sensitive genotypes. Recombination, which
occurs between gametocytes taken up in the same blood
meal, is a force which can disrupt these associations, par-
ticularly in high transmission settings and it has been
proposed that high recombination might slow the spread
of resistance in such areas [51,52]. Models have indicated
that recombination can counteract the effect of drug
pressure most effectively when the resistance alleles
involved are rare, or when drug pressure is low [4,52,53].
The evidence of this study endorses this conclusion since
the population-wide association of dhfr triple and dhps
double mutant alleles was not significant when drug pres-
sure was weak but became apparent immediately drug
pressure increased. This is a significant consideration in
the era of combination treatments for malaria. It suggests
that in high transmission settings there may be value in
using a suite of anti-malarial drugs for different treatment
applications such as intermittent preventive treatment in
pregnancy or intermittent preventive treatment of infants
rather than blanket use of the same regimen across all
malaria treatment applications.
It is widely agreed that malaria treatments should be
used in a manner which will minimize drug pressure and
limit the growth of resistance. The difficulty lies in gath-
ering empirical support for specific policy alternatives in
order to achieve this. Measurements from a variety of dif-
ferent endemic contexts are needed in order to evaluate
the effects of policy and drug resistance and the body of
evidence from the field is growing [54]. A key observation
here is that when resistance alleles are present at low fre-
quency and selection is applied they then spread rapidly.
Clearly the first emphasis of policy should always be to
minimize the emergence of new mutations and this might
be achieved through use of combination therapy. Since
this study observed a strong link between government
guidelines on treatment practice and drug pressure this is
encouraging to the view strategic policy on treatment has
the potential to be used in prolonging the useful life of
drugs in rural Africa.
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